PT - JOURNAL ARTICLE AU - Churiwal, Mehal AU - Tompkins, Kathleen AU - Streeter, Gabrielle AU - Litel, Christy AU - Mason, Sydney AU - Lin, Kelly AU - Muller, Meredith AU - Chhetri, Srijana AU - Belvin, Tia AU - Basham, Christopher AU - Whittelsey, Maureen AU - Rapp, Tyler AU - Premkumar, Lakshmanane AU - Cerami, Carla AU - Lin, Jessica T. TI - Symptom burden, viral load, and antibody response to ancestral SARS-CoV-2 strain [D614G] in an outpatient household cohort AID - 10.1101/2024.10.27.24316219 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.27.24316219 4099 - http://medrxiv.org/content/early/2024/10/29/2024.10.27.24316219.short 4100 - http://medrxiv.org/content/early/2024/10/29/2024.10.27.24316219.full AB - Background Early in the SARS-CoV-2 pandemic, description of COVID-19 illness among non-hospitalized patients was limited. Data from household cohorts can help reveal the full spectrum of disease and the potential for long-term sequelae, even in non-severe disease.Methods Daily symptom diaries were collected in a US household cohort of SARS-CoV-2 infection from April to November 2020, during the pre-COVID vaccine period. SARS-CoV-2 nasal viral loads were measured at study entry and weekly until day 21; serologic testing was performed at study entry and day 28. A subset of volunteers underwent an additional assessment 8-10 months later. Participants who met the criteria for early infection—testing antibody-negative at study entry but PCR-positive either at baseline or during follow-up—were included in this analysis (n=143).Results Daily symptoms were ascertained in 143 outpatients with acute COVID-19, including 60 index cases who sought testing and 83 of their household contacts. Asymptomatic cases comprised 16% (13/83) of SARS-CoV-2 infections detected among household contacts. Among 119 persons with mild or moderate illness, the number of symptoms peaked 3 or 4 days after symptom onset. Fever and anosmia occurred in nearly half of participants. Symptom severity was associated with increased age, viral load, and cardiovascular disease. Increased BMI was associated with a higher antibody level at day 28, independent of symptom severity. Those with a higher day 28 antibody level were more likely to develop symptoms consistent with post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID-19, 8-10 months later.Conclusions Fever, anosmia, as well as asymptomatic infection were common features of COVID-19 non-severe illness when the D614G variant circulated in the US, before the availability of vaccines or outpatient therapies. Antibody levels following acute infection were linked to the development of symptoms of PASC 8-10 months later.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04445233Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board at the University of North Carolina and is registered at clinicaltrials.gov (NCT04445233). All participants (or their parents/guardians) gave written, informed consent. Minors over the age of 7 provided assent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.